Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M42.6Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-8.6
Enterprise Value $M20.8EPS (TTM) $-0.9Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.610-y EBITDA Growth Rate %-5.8Quick Ratio7.0Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %5.4Current Ratio7.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-86.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-138.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M29.0ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GALT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GALTGeorge Soros 2014-06-30 Sold Out -0.01%$10.23 - $14.81
($12.43)
$ 1.47-88%Sold Out0
GALTGeorge Soros 2014-03-31 Buy 0.01%$8.025 - $18.3
($14.02)
$ 1.47-90%New holding48,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GALT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


GALT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CZIRR JAMES CDirector 2016-04-20Sell44,312$1.67-11.98view
10X Fund, L.P.10% Owner 2016-04-20Sell44,312$1.67-11.98view
Greenberg ArthurDirector 2016-01-05Buy1,666$1.72-14.53view
AMELIO GILBERT FDirector 2015-11-30Sell100$2.1-30view
TRABER PETER GPresident & CEO 2015-08-12Buy2,000$2-26.5view
TRABER PETER GPresident & CEO 2015-06-01Buy4,000$2.53-41.9view
FREEMAN KEVIN DDirector 2015-06-01Buy2,083$2.7-45.56view
AMELIO GILBERT FDirector 2014-12-15Sell110$3.69-60.16view
Greenberg ArthurDirector 2014-08-19Buy1,000$4.56-67.76view
FREEMAN KEVIN DDirector 2014-08-15Buy1,000$4.7-68.72view

Press Releases about GALT :

Quarterly/Annual Reports about GALT:

News about GALT:

Articles On GuruFocus.com
No related article found.

More From Other Websites
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 20 2016
Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating... Jun 02 2016
Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating... Jun 02 2016
GALECTIN THERAPEUTICS INC Financials May 19 2016
Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in... May 16 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 16 2016
Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in... May 16 2016
Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH... May 11 2016
Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH... May 11 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 11 2016
Galectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update May 10 2016
Galectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update May 10 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 10 2016
GALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 10 2016
Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at... May 05 2016
Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at... May 05 2016
Edited Transcript of GALT earnings conference call or presentation 15-Mar-16 12:30pm GMT Apr 12 2016
Galectin Therapeutics to Present at Needham & Company's 15th Annual Healthcare Conference Apr 07 2016
Galectin Therapeutics to Present at Needham & Company’s 15th Annual Healthcare Conference Apr 07 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 15 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)